BTIG analyst Ryan Zimmerman maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report) today and set a price target of $117.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Ryan Zimmerman has given his Buy rating due to a combination of factors influencing Zimmer Biomet Holdings’ stock. The shares are currently trading at historically low valuation levels, which presents a potential opportunity for investors. Despite recent market share losses in the U.S. knee and hip segments, Zimmer Biomet remains a leader in these areas and is actively addressing these challenges by introducing new products to fill gaps in their portfolio.
Moreover, the company’s valuation appears attractive, trading at a lower P/E ratio compared to its large-cap MedTech peers, despite having a higher multi-year top-line CAGR. The anticipated easing of comparisons in the second half of 2025, along with the integration of Paragon 28 and new product launches, are expected to drive top-line growth. Additionally, from a technical perspective, the stock is at a level that has historically acted as support, suggesting a potential for stabilization and upward movement. These factors combined support Zimmerman’s Buy rating with a price target of $117, based on a 13.0x EPS estimate.
According to TipRanks, Zimmerman is an analyst with an average return of -3.0% and a 40.49% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Zimmer Biomet Holdings, and Globus Medical.